HEDS is part of the School of Health and Related Research (ScHARR) at the University of Sheffield. We undertake research, teaching, training and consultancy on all aspects of health related decision science, with a particular emphasis on health economics, HTA and evidence synthesis.

Thursday, 23 February 2012

Recent CUAs

Twice each month the CEA Registry Blog lists recently published cost utility studies and associated papers.  45 papers were listed this time. Here's a few in our areas of research interest:

Kondo M, Hoshi SL, Ishiguro H, et al. Economic evaluation of the 70-gene prognosis-signature (MammaPrint(®)) in hormone receptor-positive, lymph node-negative, human epidermal growth factor receptor type 2-negative early stage breast cancer in Japan. Breast Cancer Res Treat. 2012 Feb 8. [Epub ahead of print] PubMed PMID: 22315134.

Schwenkglenks M, Toward TJ, Plent S, et al. Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of acute ST-segment elevation myocardial infarction. Heart. 2012 Feb 7. [Epub ahead of print] PubMed PMID: 22313548.

Hedden L, O'Reilly S, Lohrisch C, et al. Assessing the Real-World Cost-Effectiveness of Adjuvant Trastuzumab in HER-2/neu Positive Breast Cancer. Oncologist. 2012 Feb 2. [Epub ahead of print] PubMed PMID: 22302231.

Hedden L, Kennecke H, Villa D, et al. Incremental cost-effectiveness of the pre- and post-bevacizumab eras of metastatic colorectal cancer therapy in British Columbia, Canada. Eur J Cancer. 2012 Feb 9. [Epub ahead of print] PubMed PMID: 22325838.